Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Current Deferred Revenue (2016 - 2018)

VYNE Therapeutics' Current Deferred Revenue history spans 3 years, with the latest figure at $1.8 million for Q1 2018.

  • For Q1 2018, Current Deferred Revenue changed N/A year-over-year to $1.8 million; the TTM value through Mar 2018 reached $1.8 million, changed N/A, while the annual FY2017 figure was $1.8 million, 0.0% changed from the prior year.
  • Current Deferred Revenue reached $1.8 million in Q1 2018 per VYNE's latest filing, roughly flat from $1.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.8 million in Q4 2016 to a low of $1.8 million in Q4 2016.
  • Average Current Deferred Revenue over 3 years is $1.8 million, with a median of $1.8 million recorded in 2016.
  • The largest YoY upside for Current Deferred Revenue was 0.0% in 2017 against a maximum downside of 0.0% in 2017.
  • A 3-year view of Current Deferred Revenue shows it stood at $1.8 million in 2016, then changed by 0.0% to $1.8 million in 2017, then changed by 0.0% to $1.8 million in 2018.
  • Per Business Quant, the three most recent readings for VYNE's Current Deferred Revenue are $1.8 million (Q1 2018), $1.8 million (Q4 2017), and $1.8 million (Q4 2016).